Orforglipron

Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete[1].

Product Specifications

CAS Number

[2212020-52-3]

Product Name Alternative

LY3502970; GLP-1 receptor agonist 1

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

GCGR

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/orforglipron.html

Purity

99.64

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

C[C@@H]1[C@](N2C3=CC=C([C@]4([H])CC(C)(OCC4)C)C=C3C=C2C(N5[C@H](C6=C(N7C(N(C8=CC=C(N(N=C9)C)C9=C8F)C=C7)=O)N(C%10=CC(C)=C(C(C)=C%10)F)N=C6CC5)C)=O)(C(N%11)=NOC%11=O)C1

Molecular Formula

C48H48F2N10O5

Molecular Weight

882.96

Precautions

H302, H315, H319, H335

References & Citations

[1]Pyrazolopyridine derivative having glp-1 receptor agonist effect. WO2018056453A1|[2]Kawai T, Sun B, Yoshino H, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci U S A. 2020;117 (47) :29959-29967.